Literature DB >> 19890879

Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions.

Ignasi Rodríguez-Pizà1, Yvonne Richaud-Patin, Rita Vassena, Federico González, María José Barrero, Anna Veiga, Angel Raya, Juan Carlos Izpisúa Belmonte.   

Abstract

The availability of induced pluripotent stem cells (iPSCs) has created extraordinary opportunities for modeling and perhaps treating human disease. However, all reprogramming protocols used to date involve the use of products of animal origin. Here, we set out to develop a protocol to generate and maintain human iPSC that would be entirely devoid of xenobiotics. We first developed a xeno-free cell culture media that supported the long-term propagation of human embryonic stem cells (hESCs) to a similar extent as conventional media containing animal origin products or commercially available xeno-free medium. We also derived primary cultures of human dermal fibroblasts under strict xeno-free conditions (XF-HFF), and we show that they can be used as both the cell source for iPSC generation as well as autologous feeder cells to support their growth. We also replaced other reagents of animal origin (trypsin, gelatin, matrigel) with their recombinant equivalents. Finally, we used vesicular stomatitis virus G-pseudotyped retroviral particles expressing a polycistronic construct encoding Oct4, Sox2, Klf4, and GFP to reprogram XF-HFF cells under xeno-free conditions. A total of 10 xeno-free human iPSC lines were generated, which could be continuously passaged in xeno-free conditions and maintained characteristics indistinguishable from hESCs, including colony morphology and growth behavior, expression of pluripotency-associated markers, and pluripotent differentiation ability in vitro and in teratoma assays. Overall, the results presented here demonstrate that human iPSCs can be generated and maintained under strict xeno-free conditions and provide a path to good manufacturing practice (GMP) applicability that should facilitate the clinical translation of iPSC-based therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19890879     DOI: 10.1002/stem.248

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  43 in total

1.  The effect of topography on differentiation fates of matrigel-coated mouse embryonic stem cells cultured on PLGA nanofibrous scaffolds.

Authors:  Mohammad Massumi; Mozhgan Abasi; Hamideh Babaloo; Panieh Terraf; Mojtaba Safi; Mahdi Saeed; Jalal Barzin; Mojgan Zandi; Masoud Soleimani
Journal:  Tissue Eng Part A       Date:  2011-12-14       Impact factor: 3.845

Review 2.  Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells.

Authors:  M Nizzardo; C Simone; M Falcone; F Locatelli; G Riboldi; G P Comi; S Corti
Journal:  Cell Mol Life Sci       Date:  2010-07-29       Impact factor: 9.261

Review 3.  Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis.

Authors:  Peter C Gray; Wylie Vale
Journal:  FEBS Lett       Date:  2012-02-01       Impact factor: 4.124

4.  Derivation, Expansion, and Motor Neuron Differentiation of Human-Induced Pluripotent Stem Cells with Non-Integrating Episomal Vectors and a Defined Xenogeneic-free Culture System.

Authors:  Wentao Hu; Yongpei He; Yongjie Xiong; Hong Lu; Hong Chen; Limin Hou; Zhandong Qiu; Yu Fang; Suming Zhang
Journal:  Mol Neurobiol       Date:  2015-02-10       Impact factor: 5.590

Review 5.  The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.

Authors:  Zachary S Scheiner; Sohel Talib; Ellen G Feigal
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

Review 6.  Methods for making induced pluripotent stem cells: reprogramming à la carte.

Authors:  Federico González; Stéphanie Boué; Juan Carlos Izpisúa Belmonte
Journal:  Nat Rev Genet       Date:  2011-02-22       Impact factor: 53.242

7.  Comparison of the characteristics of mesenchymal stem-like cells derived by integration-free induced pluripotent stem cells in different single-cell culture media under feeder-free conditions.

Authors:  Mamoru Ueda; Yoshiya Hashimoto; Yoshitomo Honda; Shunsuke Baba; Shosuke Morita
Journal:  Med Mol Morphol       Date:  2018-11-16       Impact factor: 2.309

Review 8.  Cell replacement therapy is the remedial solution for treating Parkinson's disease.

Authors:  Venkatesan Dhivya; Vellingiri Balachandar
Journal:  Stem Cell Investig       Date:  2017-06-30

Review 9.  A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards.

Authors:  Nicholas M Mordwinkin; Paul W Burridge; Joseph C Wu
Journal:  J Cardiovasc Transl Res       Date:  2012-11-15       Impact factor: 4.132

10.  Reduction of N-glycolylneuraminic acid in human induced pluripotent stem cells generated or cultured under feeder- and serum-free defined conditions.

Authors:  Yohei Hayashi; Techuan Chan; Masaki Warashina; Masakazu Fukuda; Takashi Ariizumi; Koji Okabayashi; Naoya Takayama; Makoto Otsu; Koji Eto; Miho Kusuda Furue; Tatsuo Michiue; Kiyoshi Ohnuma; Hiromitsu Nakauchi; Makoto Asashima
Journal:  PLoS One       Date:  2010-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.